18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Technosphere Insulin
Technosphere Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Male and females patients from 18 to <80 years of age
- Clinical diagnosis of type 2 diabetes mellitus
- Duration of diabetes of >3 years and <20 years
- Glycemic control at upper end of acceptable level or sub-optimal in control (HbA1c between 7.0% and 12?0%)
- Confirmation of diagnosis of diabetes such as a history of 2 hour postprandial blood glucose >11.1 mmol/L (200 mg/dL) or following a glucose tolerance test
- A minimum of 2 months of treatment with a stable dose of one or more of the following anti-hyperglycemic agents: sulphonylureas, alpha glucosidase inhibitors, metformin, meglitinides, thiazolidinediones and/or Lantus basal insulin therapy
- FBG:>6 mmol/L (108 mg/dL)
- C-peptide: >0.5 nmol/L
- BMI <38 kg/m2
- Baseline DLco, FVC, FEV1 >75% of predicted normal
- Subjects who, in the opinion of the Investigator, will be able to complete this study
- Written informed consent
Exclusion Criteria:
- Severe complications of diabetes including history of: blindness from or grade III or IV diabetic retinopathy, renal failure requiring dialysis or transplantation, amputation of limbs or digits related to diabetic vasculopathy or foot ulcers
- Treatment with another investigational drug within 3 months prior to study entry and for the duration of the study
- History of drug or alcohol dependency
- Significant hepatic disease (as evidenced by ALT or AST >3 times the normal upper reference range or bilirubin >1.5 times the normal upper reference range)
- Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females) or proteinuria >1,000 mg/24 hours
- History of chronic obstructive pulmonary disease, or history of other known chronic pulmonary diseases, such as reactive airway disease, chronic bronchitis, emphysema, or asthma
- Heart disease graded as class III or class IV according to New York Heart Association criteria
- Prior treatment with , or participation in a clinical study involving an inhaled insulin product
- Smokers
- Current use of preprandial or prandially administered fast-acting or rapid acting insulin or insulin analogs
- Previous participation in a TI or TP clinical trial
- Allergy to insulin or to any drugs to be used as part of the clinical trial
- History of malignancy within 5 years of study entry (other than basal cell carcinoma)
- Anemia (hemoglobin level less than 11 g/dL for females or 12 g/dL for males at study entry)
- Diagnosis of Acquired Immunodeficiency Syndrome (AIDS) and Aids Related Complex A major psychiatric disorder that will preclude satisfactory participation in this study
- Subjects who have had a myocardial infarction or stroke within the preceding 6 months
- Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine
- History of severe or multiple allergies
- Progressive fatal disease
- Recent loss (within the past 2 months) of >5% of body weight
- Evidence of "moderate" or greater ketones in urine or history of ketoacidosis
- Use of medications known to modify glucose metabolism or the ability to recover from hypoglycemia such as oral, parenteral and inhaled steroids, or greater than 25 mg hydrochlorothiazide daily
- Women who are pregnant or lactating
- Women of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, condoms or diaphragms with spermicide, intrauterine devices, or surgical sterilization).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Technosphere Insulin
Technosphere Inhalation Powder
Arm Description
Outcomes
Primary Outcome Measures
HbA1c change from baseline (week 6) to end of treatment (week 17)
Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline.
Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after TI administration
Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline)
Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after Technosphere Placebo administration
Secondary Outcome Measures
Fasting blood glucose concentration compared to week 6 (baseline)
Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00511732
Brief Title
18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
Official Title
A Randomized, Double-blind, Controlled, Stepwise Titration Study to Evaluate Dose Response to Prandial Administration of Inhaled Technosphere/Insulin or Technosphere in Patients With Type 2 Diabetes Mellitus Who Are Sub-optimally Treated
Study Type
Interventional
2. Study Status
Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
June 2004 (undefined)
Primary Completion Date
August 2005 (Actual)
Study Completion Date
August 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mannkind Corporation
4. Oversight
5. Study Description
Brief Summary
Designed to evaluate dose response of force-titrated prandial administration of TI as compared to placebo (TP) in subjects with Type 2 diabetes who were suboptimally controlled
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
227 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Technosphere Insulin
Arm Type
Experimental
Arm Title
Technosphere Inhalation Powder
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Technosphere Insulin
Intervention Description
Technosphere Insulin Inhalation Powder
Intervention Type
Drug
Intervention Name(s)
Technosphere Placebo
Intervention Description
Technosphere Inhalation Powder
Primary Outcome Measure Information:
Title
HbA1c change from baseline (week 6) to end of treatment (week 17)
Time Frame
measured from week 6 (baseline) to week 17
Title
Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline.
Description
Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after TI administration
Time Frame
at weeks 4, 6, 11 and 17
Title
Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline)
Description
Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after Technosphere Placebo administration
Time Frame
at weeks 4, 6, 11 and 17
Secondary Outcome Measure Information:
Title
Fasting blood glucose concentration compared to week 6 (baseline)
Time Frame
at weeks 4, 6, 11 and 17
Title
Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations
Time Frame
18 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and females patients from 18 to <80 years of age
Clinical diagnosis of type 2 diabetes mellitus
Duration of diabetes of >3 years and <20 years
Glycemic control at upper end of acceptable level or sub-optimal in control (HbA1c between 7.0% and 12?0%)
Confirmation of diagnosis of diabetes such as a history of 2 hour postprandial blood glucose >11.1 mmol/L (200 mg/dL) or following a glucose tolerance test
A minimum of 2 months of treatment with a stable dose of one or more of the following anti-hyperglycemic agents: sulphonylureas, alpha glucosidase inhibitors, metformin, meglitinides, thiazolidinediones and/or Lantus basal insulin therapy
FBG:>6 mmol/L (108 mg/dL)
C-peptide: >0.5 nmol/L
BMI <38 kg/m2
Baseline DLco, FVC, FEV1 >75% of predicted normal
Subjects who, in the opinion of the Investigator, will be able to complete this study
Written informed consent
Exclusion Criteria:
Severe complications of diabetes including history of: blindness from or grade III or IV diabetic retinopathy, renal failure requiring dialysis or transplantation, amputation of limbs or digits related to diabetic vasculopathy or foot ulcers
Treatment with another investigational drug within 3 months prior to study entry and for the duration of the study
History of drug or alcohol dependency
Significant hepatic disease (as evidenced by ALT or AST >3 times the normal upper reference range or bilirubin >1.5 times the normal upper reference range)
Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females) or proteinuria >1,000 mg/24 hours
History of chronic obstructive pulmonary disease, or history of other known chronic pulmonary diseases, such as reactive airway disease, chronic bronchitis, emphysema, or asthma
Heart disease graded as class III or class IV according to New York Heart Association criteria
Prior treatment with , or participation in a clinical study involving an inhaled insulin product
Smokers
Current use of preprandial or prandially administered fast-acting or rapid acting insulin or insulin analogs
Previous participation in a TI or TP clinical trial
Allergy to insulin or to any drugs to be used as part of the clinical trial
History of malignancy within 5 years of study entry (other than basal cell carcinoma)
Anemia (hemoglobin level less than 11 g/dL for females or 12 g/dL for males at study entry)
Diagnosis of Acquired Immunodeficiency Syndrome (AIDS) and Aids Related Complex A major psychiatric disorder that will preclude satisfactory participation in this study
Subjects who have had a myocardial infarction or stroke within the preceding 6 months
Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine
History of severe or multiple allergies
Progressive fatal disease
Recent loss (within the past 2 months) of >5% of body weight
Evidence of "moderate" or greater ketones in urine or history of ketoacidosis
Use of medications known to modify glucose metabolism or the ability to recover from hypoglycemia such as oral, parenteral and inhaled steroids, or greater than 25 mg hydrochlorothiazide daily
Women who are pregnant or lactating
Women of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, condoms or diaphragms with spermicide, intrauterine devices, or surgical sterilization).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anders Boss
Organizational Affiliation
Mannkind Corporation
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs